Marcos Kulmann: IVM Is Moving to Another Level – What Will It Take to Get There?
Marcos Kulmann, Scientific Director at Nilo Frantz Medicina Reprodutiva, shared on LinkedIn:
“IVM has been discussed in reproductive medicine for years.
But the recent agreement for Ferring to acquire Gameto signals something important: the conversation is moving beyond whether in vitro maturation can work.
The next question is whether it can become more reproducible, scalable and broadly applicable.
Gameto has been developing Fertilo, an IVM platform that uses stem cell derived ovarian support cells to help immature oocytes mature outside the body.
Ferring’s proposed acquisition brings that technology closer to the infrastructure, regulatory experience and global reach of an established reproductive medicine company.
That does not mean the scientific questions are solved.
IVM already has a place in reproductive medicine, particularly for selected patients.
But broader adoption still depends on challenges we have been discussing for years:
- protocol standardization,
- reproducibility across laboratories,
- patient selection,
- clinical outcomes,
- long term follow-up.
And this is where I think the Ferring and Gameto agreement becomes particularly interesting.
For a technology to move from promising results in experienced centers to wider clinical use, good science is only one part of the equation.
It also needs development, validation, regulatory pathways, scalable laboratory processes and evidence that the results can be reproduced beyond the teams that created the technology.
This may be the next chapter for IVM.
Not proving that maturation outside the body is possible, but developing the science and infrastructure required for the technology to reach another level.
For those working in reproductive medicine, what do you think will be the biggest challenge for IVM from here?”
Robert Gilchrist, Director of Research, Discipline of Women’s Health at UNSW, shared this post, adding:
“Some interesting discussion points in this post about where IVM is heading in light of significant recent commercial developments in the sector.”
Stay informed with the latest updates in fertility and reproductive medicine on Fertility News.
-
Nov 12, 2026, 18:26Jakub Dejewski: IVF Turns 49, We’re Making It with 49 More Families
-
Nov 12, 2026, 18:16Svitlana Popkova: What IVF Should Feel Like
-
Nov 12, 2026, 18:10Caspian Ostadian: How Long Should an Embryo Rest After Warming Before Transfer?
-
Nov 12, 2026, 18:03Fereshteh Safian: Pleased to Participate in the 24th International Congress of the Iranian Society for Reproductive Medicine
-
Nov 12, 2026, 17:54Zuzana Holubcova: Assisted Reproduction Community Comes Together at 36th Congress
-
Nov 12, 2026, 17:47Mark Amols: 3 Trials, 3 Different Patients – IUI or IVF First?
-
Nov 12, 2026, 17:44Nearly 1 in 5 Women Surveyed Have Experienced Infertility – IVI Institute
-
Nov 12, 2026, 17:40Kate Ryder: Maven Care Is Now In-Network with More Than 475 Health Plans
-
Nov 12, 2026, 17:37Diana Kayal: Speaking About Trauma and Fertility at the 3rd International Conference on Gynecology and Women’s Health